Genotype-Conditioned Molecular Generation via Evidence-Grounded Multi-Objective Latent Perturbation in Diffusion Models
arXiv:2606.01461v1 Announce Type: new Abstract: Developing effective anticancer therapeutics remains challenging due to tumor heterogeneity and the absence of well-defined molecular targets across cancer subtypes. Generative models conditioned on cancer genotypes offer a promising avenue for personalized drug discovery, yet existing approaches lack explicit optimization for simultaneous sensitivity, synthesizability, and mechanistic binding plausibility. We present a latent-space optimization approach for a pretrained genotype-to-drug diffusion model, introducing a learnable perturbation over
Advances in generative AI models, particularly diffusion models, are enabling more sophisticated approaches to drug discovery and personalized medicine.
This development represents a significant step towards personalized drug discovery by leveraging AI for more effective anticancer therapeutics tailored to individual genotypes.
The ability to generate genotype-conditioned molecules with optimized properties could fundamentally alter the speed and efficacy of pharmaceutical R&D, moving towards more targeted treatments.
- · Pharmaceutical R&D
- · Oncology patients
- · Biotech companies
- · AI algorithm developers
- · Traditional drug discovery methods
- · Companies relying on broad-spectrum treatments
Accelerated discovery of novel therapeutic compounds for various diseases beyond cancer.
Reduced clinical trial failures due to more precisely designed and personalized drug candidates.
Emergence of highly individualized treatment plans based on a patient's genetic profile becoming standard medical practice.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG